Calcium Supplementation to Prevent Preeclampsia in China
This study is not yet open for participant recruitment.
Verified March 2013 by West China Second University Hospital
Sponsor:
West China Second University Hospital
Collaborators:
Sichuan Academy of Medical Sciences
Panzhihua Women And Children Hospital
THE AFFILIATED HOSPITAL OF LUZHOU MEDICAL COLLEGE
Chengdu jinjiang fuyou baojianyuan
pengzhou shi fuyou baojianyuan
Information provided by (Responsible Party):
Xinghui Liu, West China Second University Hospital
ClinicalTrials.gov Identifier:
NCT01806454
First received: March 1, 2013
Last updated: March 17, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
the purpose of this study is to determine whether calcium supplementation is effective to prevent preeclampsia in china and which dose is more suitable
| Condition | Intervention |
|---|---|
|
Preeclampsia |
Drug: calcium |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Parallel Assignment Primary Purpose: Prevention |
| Official Title: | Calcium Supplementation to Prevent Preeclampsia in China: a Multi-center, Prospective Random Trial |
Resource links provided by NLM:
MedlinePlus related topics:
Calcium
Drug Information available for:
Calcium Gluconate
U.S. FDA Resources
Further study details as provided by West China Second University Hospital:
Primary Outcome Measures:
- incidence of pre-eclampsia [ Time Frame: postpartum forty-two days ]
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: calcium A
tablets, 600mg per day,till birth
|
Drug: calcium |
|
Active Comparator: calcium B
tablets,1200mg per day,till birth
|
Drug: calcium |
Eligibility| Genders Eligible for Study: | Female |
Criteria
Inclusion Criteria:
- Nulliparity;age ≥35 years;Previous pre-eclampsia;Family history of pre-eclampsia;Multiple pregnancy;Time between pregnancies ≥10years;Body mass index ≥29;diastolic pressure ≥ 80 mm Hg before 20 weeks' gestation;Proteinuria ≥+ on more than one occasion or ≥ 300 mg/24 h before 20 weeks' gestation;Underlying medical conditions(Pre-existing hypertension;Pre-existing renal disease;Pre-existing diabetes;Presence of antiphospholipid antibodies;Chronic autoimmune disease);male sex partner's predecessor wife has Previous pre-eclampsia
Exclusion Criteria:
- first prenatal visit after 16 weeks' gestation;severe anemia;other Underlying medical conditions(such as hyperthyreosis;intrahepatic cholestasis of pregnancy )
Contacts and Locations
No Contacts or Locations Provided
More Information
No publications provided
| Responsible Party: | Xinghui Liu, Professor, West China Second University Hospital |
| ClinicalTrials.gov Identifier: | NCT01806454 History of Changes |
| Other Study ID Numbers: | hx2ck1 |
| Study First Received: | March 1, 2013 |
| Last Updated: | March 17, 2013 |
| Health Authority: | China:science & technology department of sichuan province |
Additional relevant MeSH terms:
|
Pre-Eclampsia Hypertension, Pregnancy-Induced Pregnancy Complications Calcium, Dietary |
Bone Density Conservation Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013